jesuit
proselyt
chile
discov
inca
bark
cinchona
tree
cure
malaria
addit
medicin
qualiti
cinchona
bark
describ
british
dutch
transplant
tree
javan
plantat
earli
product
quinin
payn
describ
use
quinin
treat
system
lupu
erythematosu
sle
alkaloid
contain
cinchona
bark
pamaquin
also
success
use
treat
sle
japanes
armi
occupi
java
world
war
ii
natur
suppli
quinin
lost
synthesi
antimalari
pursu
unit
state
quinacrin
compound
first
use
unpleas
side
effect
stain
skin
sclera
yellow
manner
indistinguish
icteru
chloroquin
hydroxychloroquin
found
effect
antimalari
discolor
skin
chloroquin
first
synthes
andersag
ig
farbenindustri
german
effort
find
drug
better
quinin
german
lost
interest
drug
judg
toxic
use
man
american
restudi
drug
found
effect
malaria
suffici
safe
hydroxychloroquin
synthes
propos
safer
altern
chloroquin
resist
chloroquin
antimalari
becam
problem
part
world
world
war
ii
observ
servicemen
rash
inflammatori
arthriti
took
quinacrin
chloroquin
malaria
prophylaxi
experienc
improv
autoimmun
condit
page
use
quinacrin
treat
arthriti
autoimmun
dermatolog
condit
later
chloroquin
hydroxychloroquin
also
note
favor
affect
patient
rheumatolog
diseas
time
wide
adopt
use
commonli
use
patient
rheumatoid
arthriti
ra
sle
discoid
lupu
erythematosu
polymorph
light
erupt
solar
urticaria
recurr
basal
cell
carcinoma
skin
porphyrea
cutan
tarda
antiphospholipid
antibodi
syndrom
rarer
condit
side
effect
retinopathi
discuss
chap
chapter
cover
aspect
retinopathi
quinacrin
caus
retinopathi
order
frequenc
chloroquin
hydroxychloroquin
quinacrin
chloroquin
retinopathi
first
describ
hobb
hydroxychloroquin
retinopathi
first
describ
braunvallon
quinacrin
retinopathi
rare
said
exist
nevertheless
ident
funduscop
appear
describ
literatur
chloroquin
hydroxychloroquin
articl
express
concentr
ngml
other
ml
molecular
weight
chloroquin
hydroxychloroquin
respect
one
mole
chloroquin
weigh
g
one
mole
hydroxychloroquin
weigh
g
follow
chloroquin
hydroxychloroquin
equival
ngml
ngml
respect
convers
one
chloroquin
hydroxychloroquin
equival
ml
respect
hydroxychloroquin
solubl
chloroquin
watersolubl
chloroquin
two
basic
group
correspond
quinolin
nitrogen
diethylamino
sidechain
nitrogen
ioniz
constant
respect
physiolog
ph
chloroquin
monoproton
still
solubl
lipid
abl
travers
cell
membran
howev
biproton
chloroquin
occur
lysosom
ph
sequest
prevent
travers
back
cytoplasm
see
chap
although
amount
free
drug
present
plasma
miniscul
physiolog
ph
form
drug
determin
distribut
drug
plasma
tissu
induct
acidosi
increas
concentr
drug
plasma
erythrocyt
chang
drug
concentr
tissu
larg
reservoir
steadi
state
chemic
brand
name
antimalari
drug
list
tabl
chloroquin
diphosph
oral
form
drug
chloroquin
hydrochlorid
form
use
intramuscularli
malariainduc
coma
neither
permit
routin
clinic
use
japan
follow
multipl
lawsuit
retinopathi
hydroxychloroquin
commonli
use
unit
state
chloroquin
rare
use
unit
state
multipl
lawsuit
led
winthrop
laboratori
withdraw
drug
rheumat
indic
continu
commonli
use
canada
mexico
brazil
europ
poland
turkey
south
africa
asia
structureact
studi
mani
deriv
show
halogen
substitut
posit
seven
fig
reduc
pharmacolog
activ
toxic
aryl
rather
alkyl
side
chain
decreas
therapeut
ratio
increas
alkyl
sidechain
length
five
carbon
decreas
therapeut
ratio
increas
toxic
chloroquin
bind
nucleic
acid
electrostat
forc
hydrogen
bond
van
der
waal
forc
cation
physiolog
ph
bind
ionic
melanin
polyanion
mani
neg
charg
carboxyl
group
orthosemiquinon
group
bind
forc
melanin
includ
van
der
waal
forc
aromat
ring
chloroquin
indol
nuclei
melanin
well
charg
transfer
complex
melanin
act
electron
acceptor
interact
hydroxychloroquin
melanin
parallel
chloroquin
melanin
name
famili
pigment
polyanion
polym
form
oxid
tyrosin
cellular
vesicl
call
melanosom
term
descript
chemic
eumelanin
brown
black
pheomelanin
red
yellow
occur
red
hair
melanin
occur
retin
pigment
epithelium
rpe
eye
inner
ear
substantia
nigra
brain
highest
concentr
eye
function
melanin
eye
absorb
light
prevent
scatter
protect
free
radic
although
choroid
melanin
seem
synthes
throughout
life
melanin
rpe
synthes
brief
interv
fetal
perinat
life
littl
product
thereaft
interact
melanin
complex
written
increas
melanin
relat
toxic
other
deni
maintain
agnost
viewpoint
pend
evid
also
possibl
protect
effect
rais
mechan
suggest
melanin
bind
drug
prevent
format
lamellar
bodi
bind
capac
exceed
hypothes
extens
bind
melanin
produc
high
local
gradient
drug
may
import
identifi
cell
type
particularli
affect
exampl
calcul
suggest
effect
concentr
chloroquin
cytoplasm
rpe
may
rang
ml
chloroquin
accumul
uveal
tract
pigment
anim
albino
anim
type
anim
develop
melanin
content
rpe
decreas
age
first
two
decad
life
averag
cytoplasm
volum
occupi
melanin
age
decreas
thought
occur
degrad
melanin
damag
light
free
radic
complex
granul
contain
melanolysosom
melanolypofuscin
relationship
decreas
melanin
increas
risk
increas
age
intuit
specul
chiral
carbon
side
chain
arrang
nonsuperimpos
mirror
imag
stereoisom
call
enantiom
label
r
form
clinic
use
racem
mixtur
equal
amount
r
form
enantiom
chloroquin
equipot
vitro
duck
model
malaria
mice
rat
chloroquin
potent
r
chloroquin
possibl
due
stereoselect
distribut
drug
throughout
bodi
chloroquin
highli
bound
plasma
protein
r
chloroquin
versu
sequestr
r
enantiom
ocular
tissu
greater
enantiom
toxic
enantiom
greater
r
enantiom
mammal
enantiom
chloroquin
hydroxychloroquin
excret
kidney
preferenti
compar
r
enantiom
renal
failur
associ
possibl
chloroquin
hydroxychloroquin
toxic
human
r
chloroquin
r
hydroxychloroquin
respect
nearli
complet
absorpt
oral
dose
occur
within
h
fig
fast
subject
absorpt
oral
chloroquin
hydroxychloroquin
absorpt
rel
unaffect
concomit
ingest
food
howev
intersubject
variabl
report
extent
absorpt
may
explain
part
individu
variabl
effect
toxic
pharmacokinet
chloroquin
hydroxychloroquin
similar
howev
explan
complic
differenti
sequestr
variou
tissu
bodi
continu
evolv
test
detect
drug
plasma
increasingli
sensit
result
estim
pharmacokinet
paramet
vari
wide
year
exampl
termin
halflif
chloroquin
report
various
one
day
addit
dosedepend
kinet
report
other
claim
interpret
aris
artifact
insensit
detect
method
twocompart
model
thought
best
describ
pharmacokinet
model
three
compart
consid
accur
larg
volum
distribut
v
due
extens
sequestr
drug
tissu
plasma
volum
distribut
l
chloroquin
l
hydroxychloroquin
report
normal
bodi
mass
report
volum
distribut
chloroquin
rang
lkg
depend
sensit
method
detect
chloroquin
drug
disposit
proce
three
blood
tissu
equilibr
blood
tissu
releas
tissu
back
blood
phase
halfliv
h
day
respect
peak
plasma
concentr
oral
dose
chloroquin
h
thirtythre
drug
plasma
proteinbound
effect
hypoalbuminemia
alter
immunoglobulin
composit
patient
take
well
understood
phase
termin
elimin
greatest
import
use
autoimmun
diseas
given
year
steadyst
level
emphasi
commonli
quot
median
valu
termin
elimin
halflif
day
pharmacokinet
chloroquin
differ
clinic
import
extent
black
white
patient
averag
melanin
content
black
person
estim
g
white
person
estim
mg
impli
melanin
sequestr
larg
factor
system
pharmacokinet
although
drug
continu
elut
melanin
low
level
year
cessat
ingest
lower
daili
dose
chloroquin
hydroxychloroquin
lead
lower
plateau
concentr
plasma
fig
tabl
dose
chloroquin
mgkgday
base
ideal
bodi
weight
ibw
yield
serum
concentr
ml
dose
hydroxychloroquin
mgkgday
base
ibw
yield
serum
concentr
ml
daili
dose
chloroquin
mgday
produc
plasma
concentr
equilibrium
ml
depend
bodi
mass
depend
time
reach
equilibrium
level
daili
dose
schemat
repres
fig
halflif
reach
steadyst
concentr
daili
dose
one
may
conclud
mechan
drug
elimin
firstord
process
rather
complic
depend
eliminationr
constant
plasmadrug
concentr
see
chap
p
concentr
tissu
bodi
ingest
vari
pigment
rat
order
concentr
chloroquin
singl
dose
greatest
least
uvea
liver
lung
kidney
vitreou
heart
skin
hair
brain
blood
serum
result
similar
rabbit
human
drug
bind
melanin
explain
differ
pigment
albino
anim
order
concentr
hydroxychloroquin
variou
tissu
albino
rat
similar
except
concentr
albinot
uvea
fall
approxim
level
heart
pigment
mammal
eye
highest
concentr
due
bind
melanin
similar
result
found
chronic
oral
administr
chloroquin
albino
pigment
rat
fig
limit
inform
case
accident
death
person
take
chloroquin
suicid
chloroquin
ingest
indic
similar
distribut
across
variou
tissu
human
tissu
uptak
function
dosag
nonlinear
rat
threefold
increas
dose
lead
increas
hydroxychloroquin
deposit
liver
spleen
use
way
understand
differenti
distribut
across
variou
tissu
consid
ratio
concentr
tissu
compar
plasma
concentr
tabl
concentr
chloroquin
liver
spleen
adren
gland
time
plasma
depend
speci
chosen
speci
pigment
regimen
drug
administr
within
singl
organ
larg
differ
drug
concentr
particular
tissu
exampl
chloroquin
concentr
uvea
rat
time
retina
turn
concentr
six
nine
time
vitreou
anoth
exampl
within
skin
concentr
epidermi
corium
concentr
ratio
variat
reflect
sequestr
lysosom
melanin
millimolar
level
found
lysosom
melanin
bind
quantiti
weight
clinic
unimport
differ
tissu
distribut
chloroquin
hydroxychloroquin
ident
dose
hydroxychloroquin
chloroquin
tissu
level
chloroquin
time
hydroxychloroquin
tissueplasma
concentr
ratio
chloroquin
variou
albinot
anim
rang
hydroxychloroquin
analog
tissueplasma
concentr
ratio
rang
contrast
drug
pigment
anim
tissueplasma
concentr
ratio
approxim
remain
human
tissu
year
five
year
last
ingest
chloroquin
chloroquin
metabolit
measur
urin
metabol
dealkyl
liver
fig
determin
metabolit
chloroquin
chloroquin
administ
monkey
label
metabolit
detect
two
import
desethyl
chloroquin
bisdesethyl
chloroquin
pharmacolog
activ
thought
approxim
toxic
parent
compound
differenti
efficaci
toxic
metabolit
studi
suggest
made
desethylhydroxychloroquin
might
higher
therapeut
ratio
parent
compound
hydroxychloroquin
quinolin
ring
resist
degrad
cytochrom
enzym
cyp
mediat
total
metabol
metabol
chloroquin
hydroxychloroquin
differ
number
metabolit
produc
fig
thirti
percent
oral
dose
metabol
excret
without
metabol
desethylchloroquin
concentr
dose
chloroquin
reach
chloroquin
concentr
bisdesethylchloroquin
concentr
reach
chloroquin
concentr
steadi
state
ratio
chloroquin
desethylchloroquin
ratio
hydroxychloroquin
desethylhydroxychloroquin
inhibit
cytochrom
isoenzym
drug
variat
across
individu
express
isoform
may
explain
variat
level
two
metabolit
ingest
dose
chloroquin
hydroxychloroquin
exampl
ketoconazol
inhibitor
inhibit
format
desethylchloroquin
concentr
ml
respect
cimetidin
anoth
inhibitor
increas
halflif
oral
dose
chloroquin
elimin
halfliv
chloroquin
desethylchloroquin
bisdesethylchloroquin
day
halfliv
elimin
desethyl
metabolit
longer
parent
compound
chloroquin
metabolit
found
urin
month
singl
oral
dose
caution
exercis
consid
result
test
anim
model
result
may
translat
directli
human
metabol
exampl
dog
metabol
chloroquin
glucuronid
manner
unlik
speci
lead
rel
short
halflif
excret
kidney
liver
chloroquin
hydroxychloroquin
approxim
excret
unchang
metabol
drug
kidney
excret
unchang
chang
form
fece
slough
skin
store
long
term
lean
bodi
tissu
tabl
kidney
liver
dysfunct
decreas
excret
lead
greater
drug
retent
higher
risk
retinopathi
anur
patient
compar
subject
normal
renal
function
equilibrium
level
chloroquin
higher
hydroxychloroquin
higher
declin
renal
function
may
one
mechan
age
becom
risk
factor
retinopathi
alkalin
urin
decreas
excret
acidif
urin
oral
ingest
ammonium
chlorid
increas
renal
excret
intramuscular
inject
dimercaprol
also
increas
urinari
excret
chloroquin
neither
approach
adopt
clinic
practic
practic
method
treat
chloroquin
retinopathi
commonli
use
rheumatolog
condit
effect
high
proport
case
fewer
side
effect
gold
azathioprin
penicillamin
levamisol
diagnos
prescrib
rheumatoid
arthriti
ra
sle
togeth
account
case
epidemiolog
survey
found
patient
ra
patient
sle
take
hydroxychloroquin
point
cours
diseas
antimalari
differ
mechan
action
immunomodul
therapi
make
use
combin
therapi
ra
sle
commonli
observ
patient
take
chloroquin
clinic
respons
measur
subject
improv
object
respons
laboratori
measur
activ
daili
live
reduct
flare
diseas
although
initi
embrac
patient
milder
form
sle
ra
recent
trend
use
higher
proport
patient
sle
advoc
use
sle
patient
mani
report
pool
patient
take
togeth
assumpt
diseas
drug
taken
immateri
risk
retinopathi
clinic
efficaci
may
greater
sle
ra
patient
clinic
respons
dramat
erythrocyt
sediment
rate
creactiv
protein
serum
igg
level
typic
decreas
patient
autoimmun
diseas
treat
occasion
longterm
remiss
autoimmun
diseas
possibl
progress
radiolog
document
joint
diseas
sle
use
also
improv
surviv
may
due
antiatherogen
antithrombot
effect
well
benefici
effect
lipid
profil
osteoporosi
drug
stop
benefici
effect
last
sever
week
month
diseas
activ
gener
recur
typic
increas
rate
opportunist
infect
chloroquin
prevent
immunolog
respons
antigen
protein
requir
digest
respons
cell
predigest
antigen
peptid
full
effect
may
take
month
develop
attribut
pharmacodynam
mechan
involv
immun
process
requir
observ
time
develop
howev
effect
predict
base
pharmacokinet
time
requir
satur
lysosom
see
chap
delay
onset
therapeut
effect
initi
therapi
shorten
use
higher
load
dose
first
week
month
price
increas
frequenc
gastrointestin
side
effect
doubl
daili
dose
common
first
part
cours
rheumatolog
therapi
begin
mainten
dose
lead
slower
onset
action
clinician
give
patient
drug
holiday
summer
way
assess
drug
still
requir
control
diseas
activ
practic
also
reduc
probabl
develop
rheumatologist
frequent
decreas
dose
time
one
seri
patient
patient
begun
mgday
hydroxychloroquin
daili
dose
reduc
time
import
sinc
common
intervent
ophthalmologist
suggest
dosag
reduct
cessat
respons
concern
retinopathi
approxim
patient
sle
patient
ra
eventu
cessat
drug
year
followup
mainli
inefficaci
case
ra
diseas
remiss
case
sle
rate
discontinu
highest
first
year
case
hydroxychloroquin
year
approxim
patient
sle
patient
ra
discontinu
drug
discontinu
hydroxychloroquin
may
less
common
patient
treat
sle
ra
one
seri
overal
discontinu
rate
respect
approxim
patient
stop
treatment
ocular
problem
blur
vision
corneal
deposit
stop
gastrointestin
complaint
rash
side
effect
rate
stop
depend
physician
patient
relationship
physician
patient
will
other
toler
lessthancomplet
control
diseas
activ
degre
side
effect
chloroquin
commonli
given
dose
mgday
prophylaxi
malaria
given
mg
day
treatment
acut
episod
malaria
common
dose
chloroquin
hydroxychloroquin
clinic
use
mgday
respect
regardless
height
weight
patient
cumul
dose
greater
time
use
prophylaxi
treatment
malaria
administ
patient
autoimmun
diseas
dose
excess
larg
respons
greater
preval
report
era
exampl
recommend
mgday
hydroxychloroquin
mgday
chloroquin
accept
dose
adult
weigh
lb
threshold
ibw
dose
recogn
unaccept
recogn
lb
lb
sophist
regimen
seek
dose
greater
mgkgday
base
actual
bodi
weight
abw
mgkgday
base
ibw
hydroxychloroquin
analog
ceil
chloroquin
mgkgday
base
ibw
prefer
dose
base
ibw
patient
abw
less
ibw
base
height
abw
use
determin
dose
mg
dose
chloroquin
phosphat
contain
mg
chloroquin
base
mg
dose
hydroxychloroquin
sulfat
contain
mg
hydroxychloroquin
base
rel
potenc
toxic
two
inconsist
portray
written
chloroquin
potent
toxic
hydroxychloroquin
other
said
revers
exampl
mg
hydroxychloroquin
assum
equival
mg
chloroquin
yet
anoth
report
assum
mg
chloroquin
equival
mg
hydroxychloroquin
report
state
mg
hydroxychloroquin
equival
mg
chloroquin
best
analysi
base
multipl
form
administr
differ
anim
model
human
trial
chloroquin
hydroxychloroquin
equipot
chloroquin
approxim
twice
toxic
acut
toxic
experi
anim
model
dose
die
approxim
twice
high
hydroxychloroquin
chloroquin
see
chap
likewis
subacut
chronic
toxic
studi
toler
dose
anim
approxim
twice
high
hydroxychloroquin
chloroquin
although
less
rigor
clinic
seri
human
suggest
smaller
percentag
side
effect
hydroxychloroquin
compar
chloroquin
two
given
compar
dosag
therefor
commonli
prescrib
daili
dose
chloroquin
hydroxychloroquin
consid
equal
effect
treat
autoimmun
diseas
therapeut
ratio
favor
hydroxychloroquin
see
chap
report
inconsist
way
report
drug
concentr
plasma
serum
whole
blood
concentr
use
compar
plasma
concentr
lowest
whole
blood
concentr
greatest
serum
concentr
exceed
plasma
concentr
platelet
concentr
upon
coagul
blood
platelet
content
releas
serum
plasma
level
chloroquin
effect
malaria
ml
rheumatolog
diseas
higher
plasma
level
ml
serum
concentr
chloroquin
patient
take
chloroquin
mgday
long
period
rang
ml
therapeut
whole
blood
concentr
hc
autoimmun
diseas
ml
approxim
five
time
higher
plasma
concentr
use
whole
blood
concentr
optim
preferenti
sequest
erythrocyt
leukocyt
impli
hematocrit
white
blood
cell
count
affect
whole
blood
concentr
potenti
confound
way
hand
precis
measur
higher
whole
blood
plasma
possibl
due
technic
difficulti
separ
blood
cell
platelet
plasma
make
whole
blood
suit
pharmacokinet
analys
studi
patient
rheumatoid
arthriti
patient
less
morn
stiff
rheumatoid
factor
significantli
higher
blood
concentr
hydroxychloroquin
patient
morn
stiff
presenc
rheumatoid
factor
studi
found
correl
plasma
concentr
clinic
respons
patient
take
hydroxychloroquin
ra
sle
daili
dose
mgday
associ
wide
variabl
whole
blood
concentr
studi
patient
sle
patient
inact
diseas
averag
whole
blood
concentr
ml
compar
patient
activ
diseas
higher
rate
efficaci
assur
dose
calibr
yield
whole
blood
concentr
approxim
ml
variabl
may
due
lack
adher
therapi
differ
absorpt
metabol
drug
individu
interindividu
variabl
certain
patient
may
possibl
reach
therapeut
concentr
without
exceed
daili
dose
threshold
base
ibw
consid
high
risk
caus
retinopathi
patient
take
hydroxychloroquin
graftversushost
diseas
higher
whole
blood
concentr
target
ml
concern
retinopathi
patient
balanc
seriou
natur
system
diseas
effect
plasma
concentr
effect
vitro
concentr
drug
necessarili
close
relat
drug
concentr
may
higher
local
due
intracellular
organel
sequestr
potenti
confound
includ
receptor
concentr
influenc
alcohol
smoke
genet
gender
influenc
age
perhap
inconsist
result
clinician
measur
plasma
concentr
judg
adequaci
trial
drug
one
therapeut
strategi
use
reduc
risk
retinopathi
yet
obtain
benefici
diseas
modifi
effect
antimalari
therapi
combin
chloroquin
hydroxychloroquin
quinacrin
consid
lesser
risk
caus
retinopathi
practic
term
patient
begun
hydroxychloroquin
mgday
mgkgday
base
ibw
whichev
lower
month
autoimmun
diseas
suffici
respond
quainacrin
mgday
ad
one
addit
month
respons
achiev
hydroxychloroquin
reduc
mgday
although
risk
retinopathi
quinacrin
less
retinopathi
associ
infrequ
quinacrin
antimalari
cross
placenta
concentr
eye
fetal
anim
mice
monkey
model
cord
blood
concentr
antimalari
similar
matern
blood
level
toxic
fetu
report
howev
number
mother
taken
one
drug
daili
basi
pregnant
whose
offspr
subsequ
examin
retinopathi
small
method
check
retinopathi
insensit
tabl
random
control
trial
greater
pregnanc
per
arm
would
requir
detect
differ
pregnanc
loss
alpha
error
beta
error
studi
unlik
done
therefor
practic
like
guid
evid
lesser
qualiti
studi
prospect
case
seri
rate
spontan
abort
fetal
death
fetal
distress
congenit
malform
differ
although
studi
small
littl
power
detect
small
differ
rate
flare
lupu
among
women
stop
pregnanc
frequent
women
continu
drug
throughout
pregnanc
gener
consensu
mother
use
antimalari
drug
pregnanc
need
stop
appear
affect
fetal
health
dissent
opinion
publish
base
anecdot
associ
fetal
abnorm
mother
take
pregnanc
data
use
antimalari
lactat
mother
spars
small
amount
excret
breast
milk
woman
given
mg
hydroxychloroquin
cours
h
concentr
drug
breast
milk
ml
dose
deliv
breastfeed
infant
estim
mgkgday
far
less
threshold
mgkgday
use
regul
pediatr
adult
dose
littl
evid
avail
suggest
breastfeed
mother
may
continu
therapi
hydroxychloroquin
chloroquin
prescript
consid
pregnanc
hydroxychloroquin
prefer
chloroquin
may
less
toxic
hydroxychloroquin
use
treatment
antiphospholipid
syndrom
hydroxychloroquin
less
concentr
breast
milk
chloroquin
recur
theme
paper
written
mechan
action
chloroquin
hydroxychloroquin
use
bafilomycin
ammonium
acet
ammonium
acet
cation
cross
cellular
membran
easili
use
flatten
proton
gradient
across
cell
membran
bafilomycin
drug
inhibit
vacuolar
proton
pump
decreas
acidif
intracellular
vacuol
provid
tool
diminish
uptak
lysosom
dissect
mechan
sever
candid
number
studi
exclud
mechan
produc
effect
hydroxychloroquin
inhibit
cyclooxygenas
decreas
prostaglandin
product
bind
dna
thought
clinic
import
mechan
mefloquin
bind
dna
yet
effect
antimalari
drug
benefici
effect
polymorph
light
erupt
due
lightscreen
effect
act
physic
barrier
passag
ultraviolet
radiat
chloroquin
affect
mitochondri
respir
oxid
phosphoryl
mouseliv
homogen
ratliv
mitochondria
neither
affect
adenosin
triphosph
activ
cow
visual
pigment
extract
chloroquin
affect
intern
oligonucleotid
via
acidifi
vesicl
proton
pump
inhibitor
omeprazol
may
inhibit
accumul
lysosom
decreas
ph
organel
potenti
antagon
effect
drug
immunomodul
effect
hypothes
drug
inhibit
ketoconazol
cimetidin
increas
plasma
level
pharmacolog
chloroquin
hydroxychloroquin
similarth
molecular
weight
chloroquin
hydroxychloroquin
respectivelychloroquin
hydroxychloroquin
alkyl
water
solubl
weak
amphiphil
base
readili
cross
cell
membranesmelanin
bind
weight
whether
protect
exacerb
effect
risk
retinopathi
unknownth
lysosomotrop
virtu
proton
trap
insid
acid
lysosomesabsorpt
nearli
complet
peak
plasma
concentr
h
oral
dose
volum
distribut
greater
l
termin
elimin
halflif
approxim
daysequilibrium
plasma
concentr
depend
daili
dose
ibwwith
chronic
ingest
nonalbinot
mammal
tissu
concentr
drug
highest
uvea
rpe
concentr
time
plasma
albinot
mammal
uveal
drug
concentr
approxim
heart
lipophob
concentr
fat
onetenth
plasmath
major
metabolit
desethyl
bisdesethyl
deriv
parent
drug
metabolit
pharmacolog
activ
respons
metabol
excret
kidney
excret
fece
slough
skin
store
lean
tissuesren
hepat
insuffici
lead
higher
plasma
concentr
given
daili
dose
rais
risk
toxicityth
clinic
effect
take
month
develop
load
dose
use
time
cours
follow
pharmacokinet
steadyst
concentrationsfour
hundr
milligram
per
day
hydroxychloroquin
mgday
chloroquin
accept
lesser
patient
ibw
abw
lb
morehydroxychloroquin
chloroquin
equipot
chloroquin
toxic
thu
therapeut
ratio
higher
hydroxychloroquinewhol
blood
concentr
approxim
five
time
plasma
concentr
precis
favor
pharmacokinet
measurementsa
clinic
therapeut
concentr
greater
stop
pregnanc
lactationther
action
lysosomotrop
mechan
import
clinic
effect
dichotom
effect
cell
inhibit
cell
stimul
promot
cell
stimul
combin
effect
benefici
action
autoimmun
without
penalti
increas
opportunist
infect
